Previous close | 1.1000 |
Open | 1.2200 |
Bid | 1.0000 |
Ask | 1.4000 |
Strike | 2.00 |
Expiry date | 2024-05-17 |
Day's range | 1.2200 - 1.2200 |
Contract range | N/A |
Volume | |
Open interest | 64 |
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
Per the FDA, the data submitted by Ascendis (ASND) for its hormone replacement therapy constitutes a major amendment to its previously-submitted data. A final decision is expected by Aug 14.
A week ago, Heron Therapeutics, Inc. ( NASDAQ:HRTX ) came out with a strong set of quarterly numbers that could...